Correlation Between Different Levels and Patterns of Dyslipidemia and Glomerular Filtration Rate in Patients with Type 2 Diabetes: A Cross-sectional Survey of a Regional Cohort
Overview
Biotechnology
Pathology
Authors
Affiliations
Background: Due to the high cardiovascular risk in patients with diabetic nephropathy, more attention should be paid to lipid levels and dyslipidemia in these patients. The current study investigated the association between single and mixed dyslipidemia patterns, estimated glomerular filtration rate (eGFR), and different chronic kidney disease (CKD) stages.
Methods: This cross-sectional study evaluated 4059 patients with type 2 diabetes (T2D). TG, TC, LDL-C, and HDL-C were measured. Non-HDL-C and AIP were calculated. We estimated eGFR using the CKD-EPI equation.
Results: With the progression of the kidney failure stage, mean levels of TG, LDL-C, non-HDL-C, and AIP decreased. HDL-C levels decreased with the advance of the CKD stage in men but did not change significantly in women. The prevalence of single dyslipidemia, including high LDL-C and high non-HDL-C, decreased with the advancing CKD stage. The prevalence of mixed dyslipidemia patterns, including high AIP and high LDL-C, high AIP and high non-HDL-C, showed a significant downward tendency. TG and AIP levels were negatively, and HDL-C levels were positively correlated with eGFR after adjusting for the risk factors. Also, CKD stage 3 was positively related to the risk of high TG and low HDL-C.
Conclusion: This study shows that blood lipids decreased with the progression of renal failure in patients with T2D. However, after adjustment, TG and AIP levels had negative, and HDL-C levels had a positive correlation with eGFR, which could be consistent with the hypothesis that eGFR decreases with increasing TG or AIP levels or decreasing HDL-C levels.
High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?.
Liu K, Cooper M, Chai Z, Liu F Int J Mol Sci. 2025; 26(4).
PMID: 40004147 PMC: 11855193. DOI: 10.3390/ijms26041683.
Larry M, Rabizadeh S, Mohammadi F, Yadegar A, Jalalpour A, Mirmiranpour H Health Sci Rep. 2024; 7(10):e70057.
PMID: 39355098 PMC: 11439888. DOI: 10.1002/hsr2.70057.
Wang B, Jiang C, Qu Y, Wang J, Yan C, Zhang X Lipids Health Dis. 2024; 23(1):312.
PMID: 39334373 PMC: 11429454. DOI: 10.1186/s12944-024-02288-6.
Heydarzadeh F, Mohammadi F, Yadegar A, Naeini A, Nabipoorashrafi S, Rabizadeh S Eur J Med Res. 2024; 29(1):355.
PMID: 38956709 PMC: 11218062. DOI: 10.1186/s40001-024-01950-0.
Li H, Miao X, Zhong J, Zhu Z Clin Med Insights Endocrinol Diabetes. 2024; 17:11795514241259741.
PMID: 38859965 PMC: 11163926. DOI: 10.1177/11795514241259741.